Literature DB >> 3121344

Decreased production of glutathione in patients with cirrhosis.

J M Burgunder1, B H Lauterburg.   

Abstract

Studies in animals have demonstrated the central role of the liver in regulating the circulating pool of glutathione (GSH). Most of the hepatic GSH production is released into blood and most of the circulating GSH originates in the liver. We have estimated the production of GSH in eight healthy volunteers and eight patients with cirrhosis by an analysis of the kinetics of plasma GSH. The basal plasma concentrations of free GSH were 9.3 +/- 2.4 microM in healthy volunteers and 3.6 +/- 1.1 microM in cirrhotics (P less than 0.001), and the concentrations of total GSH 16.6 +/- 6.2 microM in control subjects and 7.1 +/- 2.6 microM in cirrhotics (P less than 0.002). The concentration of GSH in the circulating pool depends on the input of GSH into this compartment and is inversely proportional to the volume of distribution of GSH (Vd) and to the fractional rate of elimination of GSH from plasma (kel). Assuming that the kinetics of endogenously produced and exogenously administered GSH are identical, Vd and kel can be calculated from the plasma concentration-time curve of a single i.v. injection of GSH. Both Vd (0.100 +/- 0.044 l kg-1 in controls and 0.131 +/- 0.043 l kg-1 in cirrhotics) and kel (0.2718 +/- 0.0555 min-1 in controls and 0.2912 +/- 0.0781 min-1 in cirrhotics) were identical in the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121344     DOI: 10.1111/j.1365-2362.1987.tb01135.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  14 in total

Review 1.  Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease: Part II. Clinical consequences and potential for pharmacological intervention in cirrhosis.

Authors:  E Pisi; G Marchesini
Journal:  Drugs       Date:  1990       Impact factor: 9.546

2.  Preclinical pharmacokinetic analysis of NOV-002, a glutathione disulfide mimetic.

Authors:  J D Uys; Y Manevich; L C Devane; L He; T E Garret; C J Pazoles; K D Tew; D M Townsend
Journal:  Biomed Pharmacother       Date:  2010-02-24       Impact factor: 6.529

Review 3.  Can paracetamol (acetaminophen) be administered to patients with liver impairment?

Authors:  Kelly L Hayward; Elizabeth E Powell; Katharine M Irvine; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-12-25       Impact factor: 4.335

4.  Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity.

Authors:  B H Lauterburg; M E Velez
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

5.  Modulation of genotoxicity of azathioprine by intracellular glutathione in hepatocytes.

Authors:  K Nagafuchi; K Miyazaki
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Pharmacokinetics, hepatic biotransformation and biliary and urinary excretion of bromosulfophthalein (BSP) in an experimental liver disease mimicking biliary cirrhosis.

Authors:  A Esteller; M D Torres; M Gomez-Bautista; E L Mariño; C Fernandez-Lastra; R Jimenez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

7.  Expression cloning of the cDNA for a polypeptide associated with rat hepatic sinusoidal reduced glutathione transport: characteristics and comparison with the canalicular transporter.

Authors:  J R Yi; S Lu; J Fernández-Checa; N Kaplowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Hepatic efflux and renal extraction of plasma glutathione: marked differences between healthy subjects and the rat.

Authors:  E Purucker; H Wernze
Journal:  Klin Wochenschr       Date:  1990-10-17

9.  Can amino acid requirements for nutritional maintenance in adult humans be approximated from the amino acid composition of body mixed proteins?

Authors:  V R Young; A E el-Khoury
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

10.  The systemic availability of oral glutathione.

Authors:  A Witschi; S Reddy; B Stofer; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.